First-in-class immunotherapy approved for multiple myeloma patients who have received three or more prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent or who ...

However, the Uncertain Future of Automatic Reimbursement in Europe Could Constrain the Uptake of Emerging Combination Regimens, According to a New Report from Decision Resources BURLINGTON, Mass., ...

The doctor is examining the patient’s feet Doctor dermatologist examines the foot on the presence of athlete’s foot. John Botson, MD, provides his perspective on including immunodulatory therapy in ...

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...

Tremendous progress has been made in the therapeutic approach to various autoimmune systemic inflammatory diseases. In rheumatology, many advances began at the time of the introduction of highly ...

When patients with inflammatory arthritis develop an infection while taking immunomodulatory drugs, temporarily interrupting the therapy does not improve outcomes, according to results from one of the ...

Announcing a new publication for Acta Materia Medica journal. Tumor-associated macrophages (TAMs) are key contributors to tumor development, accelerated tumor invasion and metastasis, and induction of ...

Table 1. Main antibacterial compounds classified according to their mechanism of action. Clindamycin, lincomycin Lincosamides Bind to the 50S subunit of the ribosome ...

Linvoseltamab-gcpt is now a preferred treatment for multiple myeloma after 4 prior therapies, joining other bispecific antibodies in the NCCN guidelines. The FDA granted accelerated approval to ...

A patient-centered approach to a cancer care delivery innovation for low income patients: Medical-legal partnership with patient navigation. This is an ASCO Meeting Abstract from the 2015 ASCO Annual ...